BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, has changed its corporate name to Scinai Immunotherapeutics Ltd. to reflect a new focus on the development of inflammation and immunology therapeutics. Recently, the company revamped its senior management team and pharmaceuticals development programs along with expansion into the contract development and manufacturing organization (CDMO) business under the banner Scinai Bioservices.

Scinai offers a multitude of services to support biotech companies through process development, as well as pilot and clinical GMP manufacturing.

According to the company, there is growing demand by small biotech companies seeking high-quality, yet affordable CDMO services to accelerate their drug development processes, including cGMP aseptic processing required for manufacturing of clinical batches. Scinai’s state-of-the-art biologics facility and capabilities are a perfect match for these clients, according to CEO, Amir Reichman.

“We are incredibly optimistic about Scinai’s growth potential and ability to deliver value to our stakeholders,” said Reichman. “The biotech sector has been through an extremely challenging time in the past 18-24 months, with low stock prices and scarce capital. We have nevertheless made tremendous progress executing our turnaround program with limited resources and believe we are at the cusp of building a significant and successful company. We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership and an expertly designed technological base.”

Reichman added: “Building on promising data of our initial NanoAb therapies, we look forward to continuing our current pipeline development and also identifying additional opportunities and developing novel solutions for unmet needs in 2023 and beyond.”